The Effectiveness of Two Anti-HIV Treatments in HIV-Infected Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00001057
First received: November 2, 1999
Last updated: March 28, 2012
Last verified: March 2012

November 2, 1999
March 28, 2012
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00001057 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
The Effectiveness of Two Anti-HIV Treatments in HIV-Infected Patients
A Phase II Randomized, Double-Blind, Placebo-Controlled Trial of the Virologic Effect of Two Different Nucleoside Treatment Strategies (Zidovudine Versus Zidovudine in Combination With Didanosine) for HIV Infection in Subjects With CD4+ Counts >= 550 Cells/mm3

To determine the effects of zidovudine (AZT) alone and in combination with didanosine (ddI) on viral load in the lymphoid tissue and blood of antiretroviral-naive, HIV-infected patients with CD4 counts greater than or equal to 550 cells/mm3.

Recent studies have shown that during the asymptomatic phase (clinical latency) of HIV infection, there is an extraordinarily large number of infected CD4+ lymphocytes and macrophages throughout the lymphoid system, both in latent and productive states. These findings support the belief that early intervention therapy with reverse transcriptase inhibitors could prolong the clinical latency period.

Recent studies have shown that during the asymptomatic phase (clinical latency) of HIV infection, there is an extraordinarily large number of infected CD4+ lymphocytes and macrophages throughout the lymphoid system, both in latent and productive states. These findings support the belief that early intervention therapy with reverse transcriptase inhibitors could prolong the clinical latency period.

Patients are randomized to receive AZT alone, AZT plus ddI, or no therapy (placebo) daily for 48 weeks. Patients are followed at weeks 2, 4, and 8, and then every 8 weeks thereafter until week 48.

Interventional
Phase 2
Primary Purpose: Treatment
HIV Infections
  • Drug: Zidovudine
  • Drug: Didanosine
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
105
May 1995
Not Provided

Inclusion Criteria

Concurrent Medication:

Allowed:

  • Antibiotics for bacterial infections as clinically indicated.
  • Recombinant erythropoietin (EPO) and G-CSF as clinically indicated for grade 3 or worse anemia and neutropenia, respectively.
  • Antipyretics.
  • Analgesics.
  • Allergy medications.
  • Oral contraceptives.
  • Nonprescription medications such as vitamins or herbal therapies.

Concurrent Treatment:

Allowed:

  • Radiation therapy to local lesion only.
  • Acupuncture.

Patients must have:

  • HIV seropositivity.
  • CD4 count >= 550 cells/mm3.
  • No ARC or AIDS conditions by CDC criteria.
  • Consent of parent or guardian if less than 18 years of age.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

  • Presence of factors predisposing to pancreatitis such as active alcoholism.
  • Other medical conditions that would interfere with study compliance.

Concurrent Medication:

Excluded:

  • Other antiretrovirals or systemic immunomodulators.
  • Systemic corticosteroids.
  • Systemic cytotoxic chemotherapy.
  • Intravenous pentamidine.

Concurrent Treatment:

Excluded:

  • Radiation therapy except to local lesion.

Patients with the following prior conditions are excluded:

  • History of chronic diarrhea, defined as more than four loose or watery stools on average daily for the past month.
  • History of grade 2 or worse peripheral neuropathy.
  • History of pancreatitis.
  • Bacterial infection requiring antibiotics within 14 days prior to study entry.

Prior Medication:

Excluded:

  • Prior HIV therapy with antiretrovirals or systemic immunomodulators.

Prior Treatment:

Excluded within 2 weeks prior to study entry:

  • Transfusion.

Active substance abuse or alcoholism.

Both
13 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00001057
ACTG 275, 11251
Not Provided
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
Not Provided
Study Chair: Erice A
Study Chair: Balfour H
Study Chair: Carey J
Study Chair: Henry K
Study Chair: Hasse A
National Institute of Allergy and Infectious Diseases (NIAID)
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP